Oridion to Present Results to New Study for the Integrated Pulmonary Index(TM) at ATACCC Conference

JERUSALEM and NEEDHAM, Massachusetts, August 17, 2010 /PRNewswire-FirstCall/ -- Oridion (SIX Swiss Exchange: ORIDN), creator of the Smart Capnography(TM) family of algorithm-based solutions, today announced that it will present the results of a new study involving its flagship Smart Capnography technology - Integrated Pulmonary Index(TM) (IPI) - at the Advanced Technology Applications for Combat Causality Care Conference (ATACCC).

"Pilot Evaluation of the Integrated Pulmonary Index on Trauma Subjects" will be presented on Tuesday, August 17, from 1800 to 2000 hours, at ATACCC, the premiere scientific meeting of the U.S. Department of Defense, addressing significant advances in trauma medicine and the unique medical needs of military combat.

Oridion and the U.S. Army Institute of Surgical Research recently conducted a joint research study of IPI, analyzing a trauma database of 110 airlifted pre-hospital trauma patients. The research was conducted under a Collaborative Research and Development Agreement.

IPI integrates four complex parameters - end-tidal CO2 (etCO2), respiration rate, pulse rate, and SpO2 (oxygen saturation) - into a single index value, enabling clinicians to quickly and easily assess a patient's ventilatory status.

IPI provides an early indication of changes in the patient's ventilatory status that may not be indicated by the current value of any of these four parameters individually. With IPI's uncomplicated, inclusive assessment, clinicians can quickly and easily monitor a patient's changing condition, facilitating more timely interventions to reduce patient risk, improve outcomes, and increase patient safety.

The study concluded that IPI was able to detect clinically significant patient events, defined prospectively, with a sensitivity of 1.0 and specificity of 0.95, which represents an unusually strong correlation. The study indicated that the Integrated Pulmonary Index may simplify monitoring of pre-hospital trauma patients and provide additional decision support in the military environment.

"In battlefield medicine, medics and other caregivers operate in dangerous and rapidly changing conditions, where swift care decisions are critical for both patient outcomes and medic safety," said David Lain, PhD, Oridion Chief Clinical Officer. "The utilization of IPI in trauma and military settings provides clinicians with a time-saving and potential life-saving technology at a most critical time."

According to Dr. Jose Salinas, PhD, Program Manager Combat Critical Care Engineering at the U.S. Army Institute for Surgical Research and a co-author of the study, clinicians without extensive experience in analyzing physiological parameters have difficulty identifying the most critical information and filtering out the less important data when presented with extensive and complicated data sets.

"This type of technology is one example of an index that combines information using a multivariate approach and provides a summary of the respiratory status of a patient," Dr. Salinas said. "Decision support systems such as this may allow the transfer of knowledge from the expert user to the inexperienced users, such as frontline medics, by providing them with additional knowledge about patient status that otherwise wouldn't be available to them. This in turn can facilitate faster triage and interventions with the goal of improving outcomes."

About Oridion

Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States and Israel.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream(R) technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology. The Company does not assure any obligation to update the forward-looking information contained in this press release.

    For further Oridion information please contact:

    Alan Adler, Chairman and Chief Executive Officer
    Walter Tabachnik, Chief Financial Officer
    Elena Gerberg, Investor Relations
    e-mail: [email protected]
    website: http://www.oridion.com
    phone: +972-2-589-9159
    address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

SOURCE Oridion Systems Ltd.